Skip to main content

Table 3 Characteristicsof “HBVreactivated” patients. 10 patients over 498 had HBV reactivation

From: Management of the HBV reactivation in isolated HBcAb positive patients affected with Non Hodgkin Lymphoma

Patient no.

Age (years)

Sex

Stage of lymphoma

Indolent aggressive (0-1)

Baseline

At diagnosis of HBV reactivation

Time of diagnosis of HBV Reactivation

Time to HBV recovery

Nuc therapy duration

Follow up HBsAg status

Outcome

HBs-Ag

HBV- DNA (UI/μL)

ALT (U/L)

Rituximab (yes/no)

Therapy

HBV- DNA (UI/μL)

Peak ALT (XN.V.)

Weeks after NHL therapy

Weeks after NUC start

Weeks

Pos/neg

 

1

50

F

IV

1

-

0

23

y

CHOP-R

350.000

4,5x

40

4

28

Neg

Alive (NHL remission)

2

73

M

IV

0

-

0

26

n

VNCOP-B

450.000

10x

24

8

Ongoing

Neg

Alive (NHL relapse)

3

64

F

I

1

-

0

34

y

Fludara-R

650.000

12x

12

4

22

Neg

Alive (NHL remission)

4

62

M

 

1

-

0

22

y

CHOP-R

130.000

4x

44

3

Ongoing

Pos

Alive (NHL relapse)

5

50

F

II

1

-

0

28

y

CHOP-R

910.000

20x

20

8

44

Neg

Alive (NHL remission)

6

71

M

IV

0

-

0

19

n

CHOP

160.000

11x

24

6

48

Neg

NHL related death

7

66

M

 

0

-

0

36

n

VNCOP-B

170.000

3,7x

20

 

Ongoing

Pos

Alive

8

70

M

IV

0

-

0

31

y

Fludara Nova -R

160.000

5,4x

72

 

Ongoing

Pos

Alive

9

52

F

I

0

-

0

29

n

CHOP

550.000

6,1x

14

7

46

Neg

Alive

10

60

M

IV

0

-

0

34

n

CEOP, Gem, VNCOP-B

340.000

6x

  

Until death

Pos

NHL related death

  1. Of this group, everyone had HBcAb positive, HBsAg, HBsAb and HBVDNA negative status prior to start NHL therapy. Five patients were treated with Rituximab-containing protocols and five without. The mean time to HBV reactivation was 26,67 (±12,21) weeks. The mean time to HBV recovery (HBVDNA negativization and normal ALT) was 5,71 (±2,06) weeks. Five patients had HBsAg negativization after a mean time of NUC therapy of 37,80 (±11,78) weeks and stopped NUC therapy. Five patients were already in NUC therapy at the end of follow-up, due to HBV infection persistence (HBsAg positivity) and/or NHL relapse. Patient 7 to 10 have missing data, because of the retrospective nature of this study.